Search Results - "BARTLETT, J. Blake"

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells by Wu, Lei, Adams, Mary, Carter, Troy, Chen, Roger, Muller, George, Stirling, David, Schafer, Peter, Bartlett, J Blake

“…Purpose: Lenalidomide has significant activity in myelodysplastic syndromes, multiple myeloma, and non-Hodgkin's lymphoma (NHL). In previous studies, natural…”
Get full text

anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells by Galustian, Christine, Meyer, Brendan, Labarthe, Marie-Christine, Dredge, Keith, Klaschka, Deborah, Henry, Jake, Todryk, Stephen, Chen, Roger, Muller, George, Stirling, David, Schafer, Peter, Bartlett, J. Blake, Dalgleish, Angus G

“…Lenalidomide (Revlimid®; CC-5013) and pomalidomide (CC-4047) are IMiDs® proprietary drugs having immunomodulatory properties that have both shown activity in…”
Get full text

The evolution of thalidomide and its IMiD derivatives as anticancer agents by Bartlett, J. Blake, Dredge, Keith, Dalgleish, Angus G

“…Thalidomide was originally used to treat morning sickness, but was banned in the 1960s for causing serious congenital birth defects. Remarkably, thalidomide…”
Get full text

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study by Sborov, Douglas W., Baljevic, Muhamed, Reeves, Brandi, Laubach, Jacob, Efebera, Yvonne A., Rodriguez, Cesar, Costa, Luciano J., Chari, Ajai, Silbermann, Rebecca, Holstein, Sarah A., Anderson, Larry D., Kaufman, Jonathan L., Shah, Nina, Pei, Huiling, Patel, Sharmila, Cortoos, Annelore, Bartlett, J. Blake, Vermeulen, Jessica, Lin, Thomas S., Voorhees, Peter M., Richardson, Paul G.

“…Summary Patients with multiple myeloma are at increased risk of vascular thromboembolic events (VTEs). This post hoc analysis evaluated VTEs in the randomised…”
Get full text

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo by Zhang, Liang, Qian, Zhengzi, Cai, Zhen, Sun, Luhong, Wang, Huaqing, Bartlett, J. Blake, Yi, Qing, Wang, Michael

“…Rituximab (RTX), a chimeric anti‐CD20 antibody, is associated with direct induction of apoptosis and antibody‐dependent cell‐mediated cytotoxicity (ADCC) with…”
Get full text

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions by Lu, Ling, Payvandi, Faribourz, Wu, Lei, Zhang, Ling-Hua, Hariri, Robert J, Man, Hon-Wah, Chen, Roger S., Muller, George W., Hughes, Christopher C.W., Stirling, David I., Schafer, Peter H., Bartlett, J. Blake

“…Lenalidomide (Revlimid®) is approved for the treatment of transfusion-dependent patients with anemia due to low- or intermediate-1-risk Myelodysplastic…”
Get full text

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN by Nooka, Ajay K., Kaufman, Jonathan L., Rodriguez, Cesar, Jakubowiak, Andrzej, Efebera, Yvonne, Reeves, Brandi, Wildes, Tanya, Holstein, Sarah A., Anderson, Larry D., Badros, Ashraf, Shune, Leyla, Chari, Ajai, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Bartlett, J. Blake, Vermeulen, Jessica, Lin, Thomas S., Richardson, Paul G., Voorhees, Peter

Get full text

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers by Wu, Lei, Parton, Anastasia, Lu, Ling, Adams, Mary, Schafer, Peter, Bartlett, J. Blake

“…We evaluated the effect of combining lenalidomide with therapeutic antibodies on antibody-dependant cell-mediated cytotoxicity (ADCC) of solid tumor cells, and…”
Get full text

Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data by Cartier, Shannon, Zhang, Bin, Rosen, Virginia M, Zarotsky, Victoria, Bartlett, J Blake, Mukhopadhyay, Pralay, Wagner, Samuel, Davis, Catherine

“…Demonstrating improved overall survival (OS) with new multiple myeloma (MM) treatments is becoming difficult because of extended survival, so progression-free…”
Get more information

Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX by Spencer, Andrew, Moreau, Philippe, Mateos, Maria-Victoria, Goldschmidt, Hartmut, Suzuki, Kenshi, Levin, Mark-David, Sonneveld, Pieter, Orlowski, Robert Z, Yoon, Sung-Soo, Usmani, Saad Z, Weisel, Katja, Reece, Donna, Ahmadi, Tahamtan, Pei, Huiling, Mayo, Wendy Garvin, Gai, Xue, Carey, Jodi, Bartlett, J Blake, Carson, Robin, Dimopoulos, Meletios A

“…High-risk multiple myeloma (MM) is often defined based on cytogenetic abnormalities, but patients who relapse early after initial therapy are considered a…”
Get full text

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity by ZHANG, Ling-Hua, LEI WU, BARTLETT, J. Blake, SCHAFER, Peter H, PAWANDI, Faribourz, RAYMON, Heather K, CHEN, Roger S, CORRAL, Laura, SHIRLEY, Michael A, NARLA, Rama Krishna, GAMEZ, Jim, MULLER, George W, STIRLING, David I

“…We have found that the synthetic compound CC-5079 potently inhibits cancer cell growth in vitro and in vivo by a novel combination of molecular mechanisms…”
Get full text

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro by Dredge, Keith, Horsfall, Rebecca, Robinson, Simon P., Zhang, Ling-Hua, Lu, Ling, Tang, Yang, Shirley, Michael A., Muller, George, Schafer, Peter, Stirling, David, Dalgleish, Angus G., Bartlett, J. Blake

“…The thalidomide analogue and immunomodulatory drug (IMiD®) lenalidomide (CC-5013, REVLIMID™) is emerging as a useful treatment for a number of cancers and has…”
Get full text

Thalidomide-derived immunomodulatory drugs as therapeutic agents by Galustian, Christine, Labarthe, Marie-Christine, Bartlett, J Blake, Dalgleish, Angus G

“…Thalidomide, a drug originally used to treat morning sickness, was removed from the market place in the early 1960s after it was found to cause serious…”
Get more information

P-329 Diagnostic Challenges Across the Multiple Myeloma Pathway: Perspectives of Primary Care Physicians and Orthopedic Specialists by Davies, Faith, Beer, Hayley, Faiman, Beth, Bartlett, J Blake, Attfield, Georgia, Gilbert, Maya, Egbase, Daniel, Mikhael, Joseph

Get full text

P-461 An overview of challenges experienced in multiple myeloma: perspectives of hematologist-oncologists and specialist nurses by Davies, Faith, Beer, Hayley, Faiman, Beth, Mikhael, Joseph, Bartlett, J Blake, Attfield, Georgia, Price, Tallulah, Gilbert, Maya

Get full text

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1 by Munshi, Nikhil C., Paiva, Bruno, Martin, Thomas, Usmani, Saad, Lin, Yi, Schecter, Jordan M., Jackson, Carolyn C., Madduri, Deepu, Zudaire, Enrique, Yeh, Tzu-min, Bartlett, J. Blake, Pacaud, Lida, Akram, Muhammad, Geng, Dong, Jagannath, Sundar, Cohen, Adam D., San-Miguel, Jesús

Get full text

Oral Abstract: MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1 by Munshi, Nikhil, Pavia, Bruno, Martin, Thomas, Usmani, Saad, Lin, Yi, Schecter, Jordan, Jackson, Carolyn, Madduri, Deepu, Zudaire, Enrique, Yeh, Tzu-Min, Bartlett, J Blake, Pacaud, Lida, Akram, Muhammad, Geng, Dong, Jagannath, Sundar, Cohen, Adam, San-Miguel, Jesús

Get full text

POSTER: MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1 by Munshi, Nikhil, Pavia, Bruno, Martin, Thomas, Usmani, Saad, Lin, Yi, Schecter, Jordan, Jackson, Carolyn, Madduri, Deepu, Zudaire, Enrique, Yeh, Tzu-Min, Bartlett, J Blake, Pacaud, Lida, Akram, Muhammad, Geng, Dong, Jagannath, Sundar, Cohen, Adam, San-Miguel, Jesús

Get full text

MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1 by Munshi, Nikhil, Pavia, Bruno, Martin, Thomas, Usmani, Saad, Lin, Yi, Schecter, Jordan, Jackson, Carolyn, Madduri, Deepu, Zudaire, Enrique, Yeh, Tzu-Min, Bartlett, J Blake, Pacaud, Lida, Akram, Muhammad, Geng, Dong, Jagannath, Sundar, Cohen, Adam, San-Miguel, Jesús

“…Minimal residual disease (MRD) negativity can predict long-term treatment outcomes in multiple myeloma. In CARTITUDE-1, treatment with chimeric antigen…”
Get full text

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin by Anderson, Larry D., Kaufman, Jonathan L., Laubach, Jacob P., Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca W., Costa, Luciano J., Nathwani, Nitya, Shah, Nina, Bumma, Naresh, Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Bartlett, J Blake, Vermeulen, Jessica, Lin, Thomas S., Voorhees, Peter M., Richardson, Paul G.

“…Introduction: Daratumumab (DARA) is approved across lines of therapy for multiple myeloma. In the primary analysis of the phase 2 GRIFFIN trial (NCT02874742)…”
Get full text